(Q36300022)

13 August 2017

1 reference

title

Benign prostatic hyperplasia: an insight into current investigational medical therapies (English)

1 reference

13 August 2017

main subject

prostatic hypertrophy

1 reference

Atul Tiwari

1

1 reference

13 August 2017

N S Krishna

series ordinal

2

1 reference

13 August 2017

Kamna Nanda

series ordinal

3

1 reference

13 August 2017

Anita Chugh

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Investigational Drugs

13 August 2017

published in

1 reference

13 August 2017

volume

14

1 reference

13 August 2017

issue

11

1 reference

13 August 2017

page(s)

1359-1372

1 reference

In vitro characterization of the alpha-adrenoceptors in human prostate

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Contractile properties of human prostate adenomas and the development of infravesical obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Natural history of prostatism: risk factors for acute urinary retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Antiandrogens: selective androgen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Gonadotropin-releasing hormone and its analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Development of GnRH antagonists for prostate cancer: new approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Gonadotropin-releasing-hormone-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Citrate metabolism of normal and malignant prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Human bladder as a novel target for vitamin D receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

GnRH antagonists in the treatment of gynecological and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Oxytocin: a paracrine regulator of prostatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

5 alpha-reductase inhibitors: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.11.1359

10.1517/13543784.14.11.1359

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference